Biktarvy vs Cabenuva
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Biktarvy | US Cabenuva | |
|---|---|---|
| Generic name | bictegravir/emtricitabine/tenofovir alafenamide | cabotegravir/rilpivirine |
| Drug class | Integrase Inhibitor + NRTI Combination | Integrase Inhibitor / NNRTI (Long-Acting Injectable) |
| Treats | HIV-1 infection | HIV-1 infection |
| Category | HIV | HIV |
| Manufacturer | Gilead Sciences | ViiV Healthcare |
| Year approved | 2018 | 2021 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $180M | — |
| Common side effects | Worsening of hepatitis B after stopping, Headache, Diarrhea, Nausea | Injection site reactions, Fever, Fatigue, Headache |
Frequently asked questions
Is Biktarvy or Cabenuva better?
Neither is universally "better." Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Cabenuva (cabotegravir/rilpivirine) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Biktarvy and Cabenuva?
Biktarvy is a Integrase Inhibitor + NRTI Combination made by Gilead Sciences, while Cabenuva is a Integrase Inhibitor / NNRTI (Long-Acting Injectable) made by ViiV Healthcare. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Biktarvy has the larger estimated TV advertising budget of the two.